By Fineline Cube 
Amgen (NASDAQ: AMGN) released its financial results for the second quarter of 2026, reporting revenue of USD 10.054 billion, representing a 10% year-over-year increase, with GAAP operating income rising to USD 3.5 billion. The company’s six core growth drivers grew 26% year-over-year, accounting for nearly 70% of product sales in Q2. For the first half of 2026, total revenue reached USD 18.672 billion.
Financial Performance Snapshot
| Metric | Q2 2026 | YoY Change | H1 2026 |
|---|---|---|---|
| Total Revenue | USD 10.054B | +10% | USD 18.672B |
| Product Sales | USD 9.537B | +9% | Not disclosed |
| GAAP Operating Income | USD 3.5B | Not disclosed | Not disclosed |
| Core Growth Drivers | ~USD 6.7B | +26% | Nearly 70% of product sales |
Product Portfolio Performance
Growth Leaders
- Repatha (evolocumab): USD 953M (+37% YoY)
- Evenity (romosozumab): USD 714M (+38% YoY)
- Enbrel (etanercept): USD 580M (-4% YoY)
Declining Franchise
- Denosumab Portfolio: USD 1.111B (-30%+ YoY)
- Prolia: USD 759M
- Xgeva: USD 352M
The significant decline in denosumab sales reflects patent expiration and biosimilar competition, while Repatha and Evenity demonstrate strong momentum in cardiovascular and osteoporosis markets respectively.
Pipeline Restructuring Decision
Amgen announced the discontinuation of AMG 513, an obesity drug candidate currently in Phase I clinical trials. This strategic decision refocuses the company’s obesity pipeline on its lead candidate:
Remaining Obesity Pipeline
- Maridebart cafraglutide (MariTide, development code AMG 133)
- Development Stage: Phase III studies
- Indications: Obesity, type 2 diabetes, and chronic weight management
- Strategic Rationale: Resource optimization toward higher-potential late-stage candidate
This move demonstrates Amgen’s disciplined approach to pipeline management, prioritizing compounds with superior efficacy profiles and commercial potential in the competitive obesity therapeutics market.
Market Analysis & Strategic Positioning
Core Growth Drivers Success
- Diversification Benefit: Strong performance across multiple therapeutic areas reduces dependency on any single product
- Innovation Validation: Newer products (Repatha, Evenity) showing robust adoption and market penetration
- Legacy Management: Proactive portfolio optimization as older franchises face generic/biosimilar pressure
Competitive Landscape
- Cardiovascular: Repatha gaining share in PCSK9 inhibitor market despite competitive pricing pressures
- Bone Health: Evenity establishing strong position in osteoporosis treatment paradigm
- Inflammation: Enbrel maintaining relevance despite biosimilar competition through established prescriber base
Forward Outlook & Guidance
- Revenue Trajectory: On track to exceed full-year 2026 guidance based on H1 performance
- Pipeline Catalysts: Multiple Phase III readouts expected for MariTide in 2027–2028
- Margin Expansion: Operating leverage from core growth drivers supporting profitability
- Capital Allocation: Continued focus on shareholder returns while investing in high-value pipeline assets
Forward‑Looking Statements
This brief contains forward-looking statements regarding financial performance, pipeline development, and strategic decisions. Actual results may differ due to risks including regulatory approvals, competitive dynamics, market access, and clinical trial outcomes.-Fineline Info & Tech